Biocoat, a manufacturer of hydrophilic biomaterial coatings for medical devices, has acquired Chempilots, a European provider of specialty polymers and production services for the medical device industry. The acquisition expands Biocoat’s biomaterial platform and aligns with its strategy of offering customized biomaterial solutions for medical innovation. Chempilots’ expertise in polymer chemistry and development of biomaterials, such as hydrogels, enhances Biocoat’s capabilities. The transaction supports Biocoat’s goal of becoming a leading provider of biocompatible medical coatings and specialty polymer products in high-growth medtech markets.
Biocoat, Inc., a specialty manufacturer of hydrophilic biomaterial coatings and coating equipment for medical devices, announced today that it has acquired Chempilots, a European provider of specialty polymers and production services to the medical device industry.
The transaction expands Biocoat’s biomaterial platform offering in alignment with its strategy to enable medical innovation by providing a comprehensive portfolio of customized biomaterial solutions. Joining Biocoat allows Chempilots to further advance their leading polymer development programs and provides access to additional markets.
Chempilots, located just north of the Danish capital of Copenhagen, is a pioneer in applied polymer chemistry. In addition to supplying specialty polymers to current customers, the team has a special focus on polymerization techniques to enable the development, scaling, and manufacturing of biomaterials, such as hydrogels, for various medical device applications.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
“We are delighted to expand our biomaterial solutions platform by joining two companies that are built on the foundation of long-term partnerships with their current and future customers,” said Jim Moran, President and CEO, Biocoat. “Both Biocoat and Chempilots supply leading medical device companies with unique chemistry products and components to support their product development. Both companies have built industry-leading customer service models that feature dedicated and expert staff focused on finding unique solutions to solve their customers’ most challenging requirements.”
Kim Sander Pedersen, CEO, Chempilots, said, “We are excited to be part of a client-focused team that is building a unique solution for companies in need of specialized biomaterial solutions.”
Chempilots represents the first add-on acquisition since GTCR invested in Biocoat in November 2022. This transaction furthers the company’s strategy to build a leading provider of biocompatible medical coatings and adjacent specialty polymer products and services, oriented around high-growth interventional medtech end markets.
Source: BioSpace